经静脉膈神经刺激治疗中枢性睡眠呼吸暂停:临床与医保支付综述
中枢性睡眠呼吸暂停(CSA)常与心力衰竭和心房颤动共存,与心血管疾病进展及死亡相关。经静脉膈神经刺激(TPNS)系统(remedē System)已获美国FDA批准用于治疗CSA,通过微创门诊手术植入,安全性和有效性良好。但患者可及性受限于美国少数专业中心及保险缺乏标准覆盖流程。本文综述TPNS背景与疗效数据,介绍其临床项目要点及覆盖与报销现状,并讨论过渡期获取第三方支付的策略。
要点
- TPNS系统已获FDA批准治疗CSA,微创植入,安全有效。
- 患者可及性受限于少数中心及保险无标准覆盖流程。
- 建立TPNS项目需多学科团队及医院支持以应对报销环境。
核心结论
- TPNS是首个获FDA批准治疗CSA的疗法,安全有效,但可及性受限于专业中心和保险覆盖流程。
- 建立可持续TPNS项目需多学科团队和医院支持,并需应对当前报销环境。
研究设计与样本
- 本文为综述,回顾TPNS的背景、疗效数据及临床项目相关方面,并介绍覆盖与报销现状。
主要发现
- CSA常与心衰和房颤共存,促进心血管疾病进展和死亡。
- TPNS系统通过微创门诊手术植入,已显示良好的安全性和有效性。
- 美国少数中心已成功建立可持续TPNS项目。
临床怎么用
- 在睡眠医学实践中建立多学科TPNS项目,并提供给适合的CSA患者。
- 了解并应对当前报销环境,以维持TPNS项目的可持续性。
局限性
- 患者可及性受限于美国少数专业中心及保险缺乏标准覆盖流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central sleep apnea (CSA) frequently coexists with heart failure and atrial fibrillation and contributes to cardiovascular disease progression and mortality. A transvenous phrenic nerve stimulation (TPNS) system has been approved for the first time by the Food and Drug Administration for the treatment of CSA. This system, remedē System (Zoll Medical, Inc.), is implanted during a minimally invasive outpatient procedure and has shown a favorable safety and efficacy profile. Currently, patient access to this therapy remains limited by the small number of specialized centers in the United States and the absence of a standard coverage process by insurers. Although a period of evaluation by insurers is expected for new therapies in their early stages, the impact on patients is particularly severe given the already limited treatment options for CSA. Implantation and management of this novel therapy require the establishment of a specialized multidisciplinary program as part of a sleep medicine practice and support from health care systems and hospitals. Several centers in the United States have been successful in building sustainable TPNS programs offering this novel therapy to their patients by navigating the current reimbursement environment. In this article, we review the background and efficacy data of TPNS and briefly address relevant aspects of the clinical activities involved in a TPNS program. The article presents the status of coverage and reimbursement for this novel therapy. We also discuss the current approach to obtaining reimbursement from third-party payors during this transitional period of evaluation by Medicare and other insurers.
引用
- Teckchandani PH, Truong KK, Zezoff D, et al. Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea: Clinical and Billing Review. Chest. 2021. PMID: 34808108. doi:10.1016/j.chest.2021.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。